Loading clinical trials...

Observational Study to Evaluate the Efficacy and Safety of Teneligliptin | Clinical Trials | Clareo Health

COMPLETED

Observational Study to Evaluate the Efficacy and Safety of Teneligliptin

Observational Study to Evaluate the Efficacy and Safety of Teneligliptin When Switched From Other DPP-4 Inhibitors in Type 2 DM With Inadequate Glycemic Control

NCT03793023•Handok Inc.

View on ClinicalTrials.gov

Summary

This study is designed as a prospective, observational, multi-centre study to evaluate the efficacy and safety of Teneligliptin when switched from other DPP-4 inhibitors in type 2 DM with inadequate glycemic control

Eligibility

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. The subject is aged ≥19 years
•2. The subject has a documented diagnosis of type 2 diabetes mellitus for at least 3 months at the screening visit.
•3. Patient who was treated with same dosage of DPP4 inhibitor for at least 12 weeks prior to baseline visit (if patient who has been treated with DPP4 inhibitor and any other antidiabetic drugs, antidiabetic drugs should also have been kept same dosage for at least 12 weeks prior to baseline.)
•4. Patient with HbA1c≥7.0% at baseline visit
•5. Patient who can be switched to Teneligliptin instead of using DPP-4 inhibitor for glycemic control based on the investigator's judgment
•6. Patient (or legal guardian, if applicable) is informed of the full nature and purpose of the study, including possible risks and side effects, and understand this information, voluntarily signed and dated the written informed consent in compliance with protocol before inclusion in the study

Exclusion Criteria

•1. Patient with hypersensitivity to the Teneligliptin
•2. Patient who treat the Teneligliptin prior to baseline visit
•3. A pregnant or lactating female patient

Locations (1)

Ajou University Hospital

Suwon, Gyeonggi-do, South Korea

Key Dates

Start Date

January 5, 2016

Primary Completion Date

September 23, 2019

Completion Date

September 23, 2019

Last Updated

January 27, 2025

Enrollment

2,983

ACTUAL participants

Conditions

Type 2 Diabetes Mellitus

Interventions

Teneligliptin 20mg

DRUG

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

RECRUITINGNA

Achieving Routine Intervention and Screening for Emotional Health

NCT06887049

Type 2 Diabetes Mellitus (T2DM)Diabetes Distress

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 27, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Observational Study to Evaluate the Efficacy and Safety of Teneligliptin

Inclusion Criteria

Exclusion Criteria

Feasibility of a Tailored Online Self-compassion Intervention

Achieving Routine Intervention and Screening for Emotional Health

A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes Mellitus

Human Immunodeficiency Virus (HIV) Food Insecurities

Impact of the New Generation Anti-diabetic Drugs on Diabetic Retinopathy

Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease